SCHEMBL22925943

SCHEMBL22925943

O=C(O)c1ccc(Nc2ncc(-c3ccc(F)c(F)c3)o2)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ VCP P55072 5/20 0.50
▸ ALOX5 P09917 1/20 0.50
▸ KDR P35968 7/20 0.45
▸ FLT1 P17948 6/20 0.45
▸ PRKAB2 O43741 1/20 0.45
▸ LCK P06239 1/20 0.45
▸ SRC P12931 1/20 0.45
▸ FLT3 P36888 1/20 0.45
▸ PRKAG1 P54619 1/20 0.45
▸ PRKAA2 P54646 1/20 0.45
▸ PRKAA1 Q13131 1/20 0.45
▸ RPS6KA1 Q15418 1/20 0.45
▸ MKNK1 Q9BUB5 1/20 0.45
▸ PRKAG3 Q9UGI9 1/20 0.45
▸ PRKAG2 Q9UGJ0 1/20 0.45
▸ PRKAB1 Q9Y478 1/20 0.45
▸ FLT4 P35916 5/20 0.43
▸ KMO O15229 1/20 0.42
▸ DGAT1 O75907 1/20 0.42
▸ P4HTM Q9NXG6 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29620955 1.00 VCP (0.50) VCPALOX5KDRFLT1PRKAB2
SCHEMBL29620878 0.88 VCP (0.46) VCPALOX5KDRFLT1PRKAB2
SCHEMBL22925871 0.88 VCP (0.46) VCPALOX5KDRFLT1PRKAB2
SCHEMBL22926099 0.88 ALOX5 (0.60) VCPALOX5KDRFLT1PRKAB2
SCHEMBL29621011 0.88 ALOX5 (0.60) VCPALOX5KDRFLT1PRKAB2
SCHEMBL29696271 0.88 ALOX5 (0.47) VCPALOX5KDRFLT1PRKAB2
SCHEMBL22925953 0.88 ALOX5 (0.47) VCPALOX5KDRFLT1PRKAB2
SCHEMBL28733778 0.84 VCP (0.64) VCPALOX5KDRFLT1FLT4
SCHEMBL22925576 0.81 TRPV1 (0.47) VCPALOX5KDRFLT1FLT4
SCHEMBL22925647 0.81 VCP (0.40) VCPALOX5KDRFLT1PRKAB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 — — US disclosed
CN-114450281-A Inhibitor compounds 辛塞拉治疗私人有限公司 2022-05-06 — — CN disclosed
WO-2021012018-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2021-01-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB VCP 595/4885ALOX5 1469/4885KDR 3951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback